Your browser doesn't support javascript.
loading
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.
Mostaghim, Anahita; Minkove, Samuel; Aguilar-Company, Juan; Ruiz-Camps, Isabel; Eremiev-Eremiev, Simeon; Dettorre, Gino M; Fox, Laura; Tondini, Carlo; Brunet, Joan; Carmona-García, MCarmen; Lambertini, Matteo; Bower, Mark; Newsom-Davis, Thomas; Sharkey, Rachel; Pria, Alessia Dalla; Rossi, Maura; Plaja, Andrea; Salazar, Ramon; Sureda, Anna; Prat, Aleix; Michalarea, Vasiliki; Van Hemelrijck, Mieke; Sita-Lumsden, Ailsa; Bertuzzi, Alexia; Rimassa, Lorenza; Rossi, Sabrina; Rizzo, Gianpiero; Pedrazzoli, Paolo; Lee, Alvin Jx; Murphy, Cian; Belessiotis, Katherine; Diamantis, Nikolaos; Mukherjee, Uma; Pommeret, Fanny; Stoclin, Annabelle; Martinez-Vila, Clara; Bruna, Riccardo; Gaidano, Gianluca; D'Avanzo, Francesca; Gennari, Alessandra; Athale, Janhavi; Eichacker, Peter; Pinato, David J; Torabi-Parizi, Parizad; Cortellini, Alessio.
Afiliación
  • Mostaghim A; Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, USA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA.
  • Minkove S; Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, USA.
  • Aguilar-Company J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Ruiz-Camps I; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Eremiev-Eremiev S; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Dettorre GM; Department of Internal Medicine, Washington University School of Medicine, St. Louis, USA.
  • Fox L; Department of Hematology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Tondini C; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Brunet J; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
  • Carmona-García M; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
  • Lambertini M; Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
  • Bower M; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Newsom-Davis T; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Sharkey R; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Pria AD; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Rossi M; Oncology Unit, Azienda Ospedaliera "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy.
  • Plaja A; Medical Oncology Department, B-ARGO Group, IGTP, Catalan Institute of Oncology-Badalona, Spain.
  • Salazar R; Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Sureda A; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Prat A; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
  • Michalarea V; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Van Hemelrijck M; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Sita-Lumsden A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Bertuzzi A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Rimassa L; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, Milan, Italy.
  • Rossi S; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Rizzo G; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Pedrazzoli P; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
  • Lee AJ; Cancer Division, University College London Hospital, London, UK.
  • Murphy C; Cancer Division, University College London Hospital, London, UK.
  • Belessiotis K; Cancer Division, University College London Hospital, London, UK.
  • Diamantis N; Medical Oncology, Barts Health NHS Trust, London, UK.
  • Mukherjee U; Medical Oncology, Barts Health NHS Trust, London, UK.
  • Pommeret F; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
  • Stoclin A; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
  • Martinez-Vila C; Fundació Althaia Manresa, Manresa, Spain.
  • Bruna R; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Ospedale Maggiore della Carità Hospital, Novara, Italy.
  • Gaidano G; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Ospedale Maggiore della Carità Hospital, Novara, Italy.
  • D'Avanzo F; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Gennari A; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Athale J; Critical Care Medicine, Mayo Clinic Arizona, Phoenix, USA.
  • Eichacker P; Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, USA.
  • Pinato DJ; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Department of Surgery and Cancer, Imperial College of London, Hammersmith Hospital Campus, London, UK.
  • Torabi-Parizi P; Critical Care Medicine Department, Clinical Center and National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
  • Cortellini A; Department of Surgery and Cancer, Imperial College of London, Hammersmith Hospital Campus, London, UK; Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128, Roma, Italy. Electronic address: a.cortellini@imperial.ac.uk.
Int J Infect Dis ; 139: 13-20, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38029831
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 / Neoplasias Límite: Humans / Male Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 / Neoplasias Límite: Humans / Male Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos